In one paragraphArticle in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 64% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed, 0 citations in OpenAlex.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
12 authors at 5 institutions in 1 country.
Joana VitalléImmunopathology Group, Biocruces Bizkaia Health Research Institute, 48903 Barakaldo, Spain.ORCID 0000-0002-5292-1851 Olatz ZenarruzabeitiaImmunopathology Group, Biocruces Bizkaia Health Research Institute, 48903 Barakaldo, Spain.
Aitana Merino-PérezImmunopathology Group, Biocruces Bizkaia Health Research Institute, 48903 Barakaldo, Spain.ORCID 0009-0002-7571-1520 Iñigo TerrénImmunopathology Group, Biocruces Bizkaia Health Research Institute, 48903 Barakaldo, Spain.ORCID 0000-0002-8099-3916 Ane OrrantiaImmunopathology Group, Biocruces Bizkaia Health Research Institute, 48903 Barakaldo, Spain.
Arantza Pacho de LucasRegulation of the Immune System Group, Biocruces Bizkaia Health Research Institute, 48903 Barakaldo, Spain.
José A IribarrenDepartment of Infectious Diseases, Donostia University Hospital, Biodonostia Health Research Institute, 20014 Donostia-San Sebastián, Spain.
Lucio J García-FraileCIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, 28029 Madrid, Spain.ORCID 0000-0002-2512-6107 Luz BalsalobreLaboratory of Microbiology, UR Salud, Infanta Sofía University Hospital, 28702 Madrid, Spain.
Laura AmoImmunopathology Group, Biocruces Bizkaia Health Research Institute, 48903 Barakaldo, Spain.
Francisco BorregoImmunopathology Group, Biocruces Bizkaia Health Research Institute, 48903 Barakaldo, Spain.ORCID 0000-0002-3105-981X BioCruces Health research Institute · ESIkerbasque · ESInstituto de Salud Carlos III · ESBiogipuzkoa Health Research Institute · ESHospital Universitario Infanta Sofía · ES
Funding
Agencia Estatal de Investigación PID2019-109583RB-I00/AEI/10.13039/501100011033Agencia Estatal de Investigación-ISCIII PI22CIII/00030Gilead Fellowship Program GLD15/00303
6 · The paper itselfAbstract
CD300a is differentially expressed among B cell subsets, although its expression in immunoglobulin (Ig)M
Indexed as
HIV InfectionsPneumococcal InfectionsAdjuvants, ImmunologicComplementarity Determining RegionsHumansImmunoglobulin MMemory B CellsStreptococcus pneumoniaeAdjuvants, ImmunologicComplementarity Determining RegionsImmunoglobulin MB cellCD300CD300aHIVIgDIgMmarginal zonememorypneumococcuspolysaccharides
Identifiers
PMID37762055
PMCPMC10530418
OpenAlexW4386484377
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390